Duexis.....

Discussion in 'Covidien' started by Anonymous, Jun 19, 2012 at 1:31 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    This is the other new product these geniuses are wanting us to promote. Great idea guys. Horizon has basically gone bankrupt and laid off there sales force trying to sell this dog. No specialist writes this and if they do it gets switched at the pharmacy to OTC or generic. Why the hell would we sign on for this POS. Now we are going to get stuck with unrealistic goals and more pressure put on us for a crap product. Also would seem to cannibalize Pennsiad Rx's. I can see wanting to license something new but ibuprofen and famotidine. Come on man. Get a life!
     

  2. Anonymous

    Anonymous Guest

    Re: Duexis.....A Flop for Horizon Pharma, Now Covidien!

    http://seekingalpha.com/article/314581-the-sun-may-not-rise-at-horizon-pharma-for-duexis

    The Sun May Not Rise At Horizon Pharma For Duexis
    December 18, 2011 | 3 commentsby: ScriptVolume | about: HZNP, includes: JNJ, PFE, PG Horizon Pharma (HZNP) recently announced the launch of Duexis, a combination of ibuprofen 800 mg and famotidine 26.6 mg, indicated for rheumatoid arthritis (RA) and osteoarthritis (OA). The Center of Disease Control estimates the prevalence of RA and OA at over 28 million Americans. For Horizon, the market potential for Duexis is substantial, but in reality, the market penetration may be disappointing. Duexis prevents one ulcer for every 10 patients when compared to ibuprofen alone, but the data does not indicate that it prevents gastrointestinal bleeding. In addition, there are market forces that may prevent Duexis from gaining any traction in the RA and OA space.

    Ibuprofen and famotidine, the active ingredients in Duexis, are available in multiple strengths on the shelves of your local pharmacy or by prescription. Ibuprofen 200 mg is sold over-the-counter by various generic manufacturers and under the trade names of Motrin by Johnson & Johnson (JNJ) and Advil by Pfizer (PFE). Similarly, famotidine is also available over-the-counter in 10 and 20 mg tablets from various generic manufacturers and under the trade name of Pepcid by Johnson & Johnson. Ibuprofen 400, 600, and 800 mg is available by prescription. Famotidine, by prescription, is available in the 20 and 40 mg tablet strengths. The same dosing regimen as Duexis can be achieved at a much lower cost with potentially the same therapeutic outcome.

    Brand Name
    Available Over-The-Counter
    Available by Prescription

    Duexis (ibuprofen and famotidine)
    Duexis
    No
    Ibuprofen – 800 mg

    Famotidine – 26.6 mg

    Ibuprofen
    Motrin, Advil
    200 mg
    400 mg, 600 mg, 800 mg

    Famotidine
    Pepcid
    10 mg, 20 mg
    20 mg, 40 mg


    If taken three times daily, Duexis provides approximately 2,400 mgs of ibuprofen and 80 mgs of famotidine per day. The 80 mgs of famotidine is important because it is at this dose that data has demonstrated to reduce ulcers from non-steroidal anti-inflammatories (NSAIDs) such as ibuprofen. Duexis delivers a fixed 800 mgs of ibuprofen – a dose that is considered on the higher end and may not be appropriate in many patients – while the generic over-the-counter/prescription combinations can deliver anywhere from 200, 400, 600 or 800 mgs per dose. Unlike Duexis, the amount of ibuprofen can be tailored to the needs of the patient. With famotidine, the patient can be instructed to take two of the 20 mgs over-the-counter tablets twice daily to achieve 80 mgs per day or by prescription, one of the 40 mgs tablets twice daily. Not only will it cost less for patients and insurance carriers to use the generic over-the-counter/prescription combinations, but the dosing regimen will be a lot more flexible for physicians and patients.

    Other strategies exist to prevent stomach ulcers in patients taking NSAIDS, with some better than Duexis. Proton-pump inhibitors (PPIs) such as omeprazole or brand name Prilosec by Procter & Gamble (PG) are available over-the-counter and proven to be more effective than famotidine. In other patients, adding misoprostol or using Celebrex instead of ibuprofen are also viable options.

    It will be difficult to justify using Duexis, especially when cost is factored in. Duexis will cost an estimated $150 per month. Equivalent, and in some cases, better generic therapeutic options are available at a fraction of that price. Looking further into the horizon, HZN-602 will encounter the same issues as Duexis. This time, it will be famotidine and Naprosyn, a different NSAID that is available over-the-counter and by prescription in generic form.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
     
  3. Anonymous

    Anonymous Guest

    What a joke!
     
  4. Anonymous

    Anonymous Guest

    Because Our CEO and Horizon CEO worked together when they were at Bayer! DUH!
     
  5. Anonymous

    Anonymous Guest

    Good luck trying to move this overpriced generic. Your doctors will be glad to see you, bringing them samples and new information on this cutting edge novel product!
     
  6. Anonymous

    Anonymous Guest

    Read the post above, easily this can be obtained with OTC alternatives! Another loser drug for Covidien with likely out of reach goals! GO COVIDIEN! What a f*#k'd up company!
     
  7. Anonymous

    Anonymous Guest

    Both of these companies suck. Sorry little pharma division but once Covidien throws you out on your ass, you'll need all the help you can get.
     
  8. Anonymous

    Anonymous Guest

    good luck with this. i sold vimovo(naproxen/nexium) and it was the worst, no coverage, $130 cash price for two otc meds. just miserable
     
  9. Anonymous

    Anonymous Guest

    Duexis WAC is $165.00. About 1.80 per pill.
     
  10. Anonymous

    Anonymous Guest

    Horizon rep here. Selling Duexis is an ABSOLUTE nightmare. And we have lists of targets that they going to give you guys. All I can say is Good Luck. I'm on my 4th set of new docs trying to sell this shitty overpiced fraud. The Docs that start to write will eventually fall off because coverage is soo poor. So, I get new docs on board until they realize prescribing this drug is a pain in the as*. This is truly a nightmare.
     
  11. Anonymous

    Anonymous Guest


    Duexis rep here to back up the previous poster. It is true, you won't be able to sell this dog.
     
  12. Anonymous

    Anonymous Guest

    But that is what Covidien mgt wants, a loser drug no one can sell, sets unrealistic goals and then fires reps for not performing magic acts!

    Get out of Covidien people, get out!!!!
     
  13. Anonymous

    Anonymous Guest

    They can kiss my ass, I'm not selling Duexis.....I asked several Docs if they had heard of it and they had not....I explained what is was and 3 out of 4 told me to not even detail such a dumbass drug....$150 a month, 3 month and 6 month study....study done on patients 65 and under with no history of ulcers....
     
  14. Anonymous

    Anonymous Guest

    No coverage for this horrible drug
     
  15. Anonymous

    Anonymous Guest

    Horrible, horrible product. Run, run fast.
     
  16. Anonymous

    Anonymous Guest

    What are you new? There is no "generic". dipstick.


     
  17. anonymous

    anonymous Guest

    I just received samples and haven't noticed any difference from taking 4 ibuprofen 3 times a day.
     
  18. anonymous

    anonymous Guest

    Since Covidien/Malinckrot whatever makes ibuprofen generic and femotidine is generic OTC, technically, YES, there is a generic option in two pills, Dipstick. You must be in "management". There is no market for an expensive dud like the big D. People have to realize that pharma sales are on the way out so get your sh..stuff together and remake your careers; the sooner the better.
     
  19. anonymous

    anonymous Guest

    The funny part is that Horizon charged $2000 per Rx. It was a major scam perpetuated by one Todd Smith, pharma bro. Look that pos up!